http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005536231-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2003-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005536231-A |
| titleOfInvention | Use of spliceosome-mediated RNA trans-splicing to bring cell-selective replication to adenovirus |
| abstract | The present invention provides methods and compositions for effecting tumor-selective cell death in cancer cells that express specific target precursor messenger RNA molecules (cancer cell-selective target pre-mRNA). The composition of the present invention interacts with one or more cancer cell target pre-mRNAs and mediates a trans-splicing reaction, resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) that can encode an adenovirus-specific protein. Conditionally replicating adenoviruses that are engineered to express one or more pre-trans-splicing molecules (PTMs) designed to Adenovirus-specific proteins include proteins that complement the essential activities required for replication of defective adenovirus. The methods and compositions of the invention can also be used to provide a method of targeting lytic adenovirus infection to cancer cells, thereby selectively destroying cancer cells. Furthermore, the adenovirus of the present invention interacts with a target pre-mRNA encoded by an infectious agent in the cell, thereby causing a PTM designed to target selective destruction of cells infected with such agent. You may operate to code. |
| priorityDate | 2002-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.